Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2011 1
2012 1
2013 1
2014 1
2015 1
2018 1
2020 1
2021 1
2022 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.
Castellet H, Ramil G, Carricondo M, Oñate G, Garrido A, Artigas A, Pratcorona M, Salamero O, Cortés-Bullich A, Vives S, Tormo M, Mascaró M, Gallardo D, Tutusaus JMM, Garcia A, Sierra J, Esteve J, Nomdedéu J; CETLAM group. Castellet H, et al. Eur J Haematol. 2025 Jun;114(6):1052-1054. doi: 10.1111/ejh.14402. Epub 2025 Feb 23. Eur J Haematol. 2025. PMID: 39988452 No abstract available.
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L; CETLAM group. Cabezón M, et al. Clin Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y. Clin Epigenetics. 2021. PMID: 33446256 Free PMC article.
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
Jimenez-Vicente C, Cardus A, Castaño-Diez S, Ramil G, Garcia-Avila S, Gomez-Perez L, Esteban D, Arribas I, Sturla AL, Lopez-Guerra M, Martinez-Roca A, Cortes-Bullich A, Perez-Valencia AI, Zugasti I, Monge I, Carcelero E, Vall-Llovera F, Vives S, Sierra J, Nomdedeu J, Oñate G, Garrido A, Pratcorona M, Pomares H, Arnan M, Guijarro F, Diaz-Beya M, Esteve J; Spanish CETLAM Group. Jimenez-Vicente C, et al. Blood Cancer J. 2025 May 14;15(1):94. doi: 10.1038/s41408-025-01298-6. Blood Cancer J. 2025. PMID: 40368916 Free PMC article. No abstract available.
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ; CETLAM Group. Valcárcel D, et al. Cancer. 2012 Jan 15;118(2):410-7. doi: 10.1002/cncr.26273. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717435 Free article.
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D; on the behalf of CETLAM Group. Díaz-Santa J, et al. Leukemia. 2020 Nov;34(11):2925-2933. doi: 10.1038/s41375-020-0784-2. Epub 2020 Mar 9. Leukemia. 2020. PMID: 32152464
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group. Nomdedéu JF, et al. Leukemia. 2013 Nov;27(11):2157-64. doi: 10.1038/leu.2013.111. Epub 2013 Apr 15. Leukemia. 2013. PMID: 23584566
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D; “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group). Díaz-Santa J, et al. Eur J Haematol. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. Epub 2022 Sep 16. Eur J Haematol. 2022. PMID: 36063368
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.
Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group. Cabezón M, et al. Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721207 Free PMC article.
Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A, Queipo de Llano MP, Sánchez JM, Brunet S, Sierra J; Spanish CETLAM Group. Muñoz L, et al. Leukemia. 2003 Jan;17(1):76-82. doi: 10.1038/sj.leu.2402708. Leukemia. 2003. PMID: 12529663
11 results